Sellas Life Sciences Group (SLS) said Tuesday that group three data showed that tambiciclib topped the benchmark for median overall survival in the ongoing phase 2 relapsed/refractory acute myeloid leukemia study.
The median overall survival for all patients in the group was 8.8 months and 8.9 months for patients with AML-myelodysplasia-related changes or AML-MRC, exceeding the historical benchmark of 2.5 months, the company said.
The overall response rate in all evaluable patients was 46% in all group three patients and 67% in AML-MRC patients, surpassing the targeted 20% ORR, the company added.
The company said phase 2 trial continues in expansion groups four and five.
Shares of Sellas Life Sciences rose 5.8% in recent trading.
Price: 1.10, Change: +0.06, Percent Change: +5.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。